Abstract
Everolimus was developed for use with cyclosporine as a new immunosuppressant in the prevention of rejection in transplant patients. It binds to FK binding protein and modulates the activities of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
